L'accès aux traitements antisida en Afrique: une analyse de la stratégie de brevet des entreprises multinationales

Samira Guennif () and Claude Mfuka
Additional contact information
Samira Guennif: CEPN - Centre d'Economie de l'Université Paris Nord (ancienne affiliation) - UP13 - Université Paris 13 - CNRS - Centre National de la Recherche Scientifique
Claude Mfuka: CEPN - Centre d'Economie de l'Université Paris Nord (ancienne affiliation) - UP13 - Université Paris 13 - CNRS - Centre National de la Recherche Scientifique

Post-Print from HAL

Abstract: According to Attaran and Gillespie-White (2001), there is no link between patents and poor access to HIV/AIDS treatments in Africa since multinationals patent a few. Nevertheless, the authors admit that multinationals patent a lot in South Africa and specific treatments in Africa. This paper shows that rule and exceptions are part of the multinationals' offensive patenting strategy. Multinationals use patenting to erect entry barriers towards southern generics producers. As a result, this strategy impedes access to medicines and hinders the industrial development of southern generics producers.

Keywords: Patent; Strategy; Multinationals; Africa; Generics producers; Antiretrovirals.; Antirétroviraux; Brevet; Stratégie; Multinationales; Afrique; Génériqueurs; Antirétroviraux. (search for similar items in EconPapers)
Date: 2005
References: Add references at CitEc
Citations:

Published in Mondes en Développement, 2005, 33 (131), pp.75-87

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:halshs-00163960

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().